Short acting GLP-1 receptor agonist (injectable)
Lixisenatide 30 µg injection twice daily
LIXI_SC_30UG_BID
Related
- All doses pooled: Lixisenatide injection
- Lixisenatide 20 ug subcutaneous once daily
- Lixisenatide 5 µg injection once daily
- Lixisenatide 10 µg injection once daily
- Lixisenatide 30 µg injection once daily
- Lixisenatide 5 µg injection twice daily
- Lixisenatide 10 µg injection twice daily
- Lixisenatide 20 µg injection twice daily
- Lixisenatide 10 µg injection
- Lixisenatide 2.5 µg injection
- Lixisenatide 5 µg injection
- Lixisenatide 20 µg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.53 (0.01 to 29.54) | 0.46 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.20 (0.70 to 7.07) | 0.34 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.48 (0.04 to 2.73) | 0.69 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.22 (0.23 to 27.00) | 0.42 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.38 (2.73 to 10.55) | 0.23 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.99 (1.62 to 15.36) | 0.31 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.01 (1.54 to 5.90) | 0.23 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.91 (0.05 to 16.65) | 0.46 |